A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation
- Registry ID
- 2025-524392-23-00
- Source registry
- CTIS
- Status
- Authorised
- Phase
- PHASE4
- Study type
- INTERVENTIONAL
- Sponsor
- Regeneron Pharmaceuticals Inc.
- Enrollment
- 120
- Last update
- 2026-08-14
Conditions
- Diseases [C] - Respiratory Tract Diseases [C08]
- Chronic obstructive pulmonary disease (COPD)
Primary outcomes
Time to first all-cause event (all-cause event may include non-elective hospital readmission, Emergency Department (ED)/urgent care visit, or death), Number of moderate or severe COPD exacerbations
Locations
Related clinical trials
- A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors
- A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non Small Cell Lung Cancer with KRAS G12C Mutation
- A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
- CONQUEST
Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
- A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
View on source registry